A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/00007168/isLanding
下载链接
链接失效反馈官方服务:
资源简介:
This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given
subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who
have previously had an inadequate response to treatment with anti-tumor necrosis factor
(anti-TNF) therapy.
提供机构:
Vivli
创建时间:
2021-06-10



